These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17039420)

  • 1. Impact of smoking on the course of Graves' disease after withdrawal of antithyroid drugs.
    Quadbeck B; Roggenbuck U; Janssen OE; Hahn S; Mann K; Hoermann R;
    Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):406-11. PubMed ID: 17039420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
    Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
    Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
    Schott M; Morgenthaler NG; Fritzen R; Feldkamp J; Willenberg HS; Scherbaum WA; Seissler J
    Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves' disease: comparison with the second generation human TRAb assay.
    Massart C; Gibassier J; d'Herbomez M
    Clin Chim Acta; 2009 Sep; 407(1-2):62-6. PubMed ID: 19576193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved prediction of relapse of Graves' thyrotoxicosis by combined determination of TSH receptor and thyroperoxidase antibodies.
    Schott M; Eckstein A; Willenberg HS; Nguyen TB; Morgenthaler NG; Scherbaum WA
    Horm Metab Res; 2007 Jan; 39(1):56-61. PubMed ID: 17226115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves' Disease Relapse.
    Tun NN; Beckett G; Zammitt NN; Strachan MW; Seckl JR; Gibb FW
    Thyroid; 2016 Aug; 26(8):1004-9. PubMed ID: 27266892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TSH receptor antibody (TRAb) assays based on the human monoclonal autoantibody M22 are more sensitive than bovine TSH based assays.
    Zöphel K; Roggenbuck D; von Landenberg P; Wunderlich G; Grüning T; Kotzerke J; Lackner KJ; Rees Smith B
    Horm Metab Res; 2010 Jan; 42(1):65-9. PubMed ID: 19830651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prospective study on the relationship between treatment duration of antithyroid drug and remission rate of Graves' disease].
    Liu C; Duan Y; Wu X
    Zhonghua Yi Xue Za Zhi; 2000 Nov; 80(11):835-7. PubMed ID: 11218878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antithyrotropin receptor antibodies in a series of Basedow's disease].
    Vidal E; Antoine E; Nadalon S; Cevallos R; Bournaud E; Vandroux JC; Bordessoule D; Loustaud V; Weinbreck P; Liozon F
    Ann Med Interne (Paris); 1988; 139(5):331-5. PubMed ID: 2462393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
    Rink T; Holle LH; Schroth HJ; Garth H
    Nuklearmedizin; 1998 May; 37(3):90-4. PubMed ID: 9604228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
    Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission.
    Eckstein AK; Lax H; Lösch C; Glowacka D; Plicht M; Mann K; Esser J; Morgenthaler NG
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):607-12. PubMed ID: 17880407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.
    Schott M; Minich WB; Willenberg HS; Papewalis C; Seissler J; Feldkamp J; Bergmann A; Scherbaum WA; Morgenthaler NG
    Horm Metab Res; 2005 Dec; 37(12):741-4. PubMed ID: 16372227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease].
    Bojarska-Szmygin A; Ciechanek R
    Wiad Lek; 2003; 56(7-8):303-7. PubMed ID: 14969154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease.
    Bojarska-Szmygin A; Janicki K; Pietura R; Janicka L
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):248-53. PubMed ID: 15314994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of an artificial neural network to predict Graves' disease outcome within 2 years of drug withdrawal.
    Orunesu E; Bagnasco M; Salmaso C; Altrinetti V; Bernasconi D; Del Monte P; Pesce G; Marugo M; Mela GS
    Eur J Clin Invest; 2004 Mar; 34(3):210-7. PubMed ID: 15025680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves' disease (GD): an international multicentre trial.
    Schott M; Hermsen D; Broecker-Preuss M; Casati M; Mas JC; Eckstein A; Gassner D; Golla R; Graeber C; van Helden J; Inomata K; Jarausch J; Kratzsch J; Miyazaki N; Moreno MA; Murakami T; Roth HJ; Stock W; Noh JY; Scherbaum WA; Mann K
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):566-73. PubMed ID: 19170704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TSH receptor antibodies for confirming the diagnosis and prediction of remission duration, in newly diagnosed Graves' disease patients.
    Aleksić A; Aleksić Z; Stojanović M
    Hell J Nucl Med; 2009; 12(2):146-50. PubMed ID: 19675869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.